Research keywords (6)：
Gynecologic Surgery
, Molecular targeted therapy
, Obstetrics and Gynecology
, Immune therapy
, Genome analysis
, Gynecologic oncology
Research theme for competitive and other funds (32)：
2023 - 2028 Development of a Novel Immunotherapy for the Cure of Ovarian Clear Cell Carcinoma
2023 - 2026 Scientific evaluation of hypotheses about "adverse reactions" to the HPV vaccine.
2023 - 2026 Exploration of novel biomarkers for ovarian clear cell carcinoma using a mouse cell line library
2023 - 2026 Development of novel cancer immunotherapy by induction of epithelial-directed CD8T cells
2023 - 2026 Exploration of intratumoural heterogeneity and developmental mechanisms based on cancer-associated genetic mutations in ovarian endometrioid carcinoma.
2022 - 2025 Analysis of single-cell HRD and intratumor heterogeneity in high-grade serous ovarian carcinoma
2022 - 2025 Investigation of personalized therapy with molecularly targeted agents for high-grade serous ovarian carcinoma
2020 - 2023 Investigation of the mechanism of development and preventive method for endometriosis-associated ovarian cancer
2018 - 2023 Development of new treatment for ovarian cancer based on intratumor heterogeneity
2019 - 2022 An Exploratory Study on Factors Affecting Ovarian Reserve Capacity in Patients with Endometriosis
2018 - 2021 Development of diagnosis of lymph node metastasis in uterine cancer by superparamagnetic iron oxide
2017 - 2020 The genome analyses for advanced and recurrent ovarian clear cell carcinoma
2017 - 2019 The establishment of new method of screening with liquid biopsy for ovarian cancer
2016 - 2019 Epigenetic profiling of cfDNA in breast cancer samples
2016 - 2018 In vivo functional genomics screen reveals mechanism of peritoneal dissemination in ovarian cancer
2016 - 2018 Investigation of the mechanism how dietary foods influence on progression of ovarian cancer.
2015 - 2018 The elucidation of the mechanisms of sensitivity and resistance to anti VEGF antibodies in ovarian cancer
2014 - 2017 Establishment of useful predictive biomarkers of chemo sensitivity for ovarian cancer patients
2014 - 2017 Fundamental research of host immune-genomics and development of new cancer therapy for ovarian cancer
2014 - 2016 The mechanism of "alteration to a cancer stem cell" in ovarian cancer
2014 - 2016 Chemoresistance through acquision of anchorage-independent cell growth in ovarian cancer.
2014 - 2016 An exploration of novel immunosuppressive factors by using immunological functional genome screening and development of new treatment strategy in ovarian cancer
2013 - 2016 Investigation of a new drug based on DNA mutation analysis in ovarian cancer.
2010 - 2013 Targeting "Evolution" in Drug Acquisition Resistance in Ovarian Cancer
2011 - 2012 Investigation of aberrant metabolism in ovarian clear cell carcinoma using bioinformatics.
2010 - 2011 Can we produce ovarian stem cells by gene expression of Yamanaka factors to ovarian cancer cell lines?
2009 - 2011 Interaction between platelet and trophoblast-Toward the elucidation of pathophysiology of PIH and IUGR-
2009 - 2011 Immune environment in the peritoneal cavity and development of novel immune therapy in ovarian cancer
2009 - 2011 Evolution of ovarian carcinoma cells through peritoneal dissemination ; genome-wide analysis and clinical application.
2009 - 2010 Development of a therapeutic agent against ovarian clear cell carcinoma based on chemogenomics.
2007 - 2008 Analysis of signaling pathways in peritoneal dissemination of ovarian cancer, which leads to investigation for their suppressor reagents.
2007 - 2008 Searching for effective drugs against ovarian clear cell carcinoma based on microarray analysis
Show all
Papers (237)：
Mamiko Ohta, Kaoru Kawasaki, Rumiko Yamamoto, Keisuke Ishii, Kazutoshi Nakano, Shinobu Akada, Kunihiko Doh, Masao Shimaoka, Hiroshi Ota, Kaori Moriuchi, et al. Possible rapid reduction of anti-RBD antibody titre after SARS-CoV-2 mRNA vaccination in pregnant women: Multicentre prospective study. The journal of obstetrics and gynaecology research. 2024
Hiroe Ito, Yoshihito Yokoyama, Satoru Kyo, Masaki Mandai, Kenzo Kosaka, Hiroaki Kobayashi, Etsuko Miyagi, Mamiko Onuki, Koji Matsumoto, Noriomi Matsumura, et al. Interim analysis of robot-assisted radical hysterectomy in Japan: a multicenter, prospective interventional single-arm clinical trial. BMC Cancer. 2024. 24. 1
Shiro Takamatsu, R Tyler Hillman, Kosuke Yoshihara, Tsukasa Baba, Muneaki Shimada, Hiroshi Yoshida, Hiroaki Kajiyama, Katsutoshi Oda, Masaki Mandai, Aikou Okamoto, et al. Molecular classification of ovarian high-grade serous/endometrioid carcinomas through multi-omics analysis: JGOG3025-TR2 study. British journal of cancer. 2024. 131. 8. 1340-1349
Noriomi Matsumura, Masaki Mandai. PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs; approval of sacituzumab govitecan for breast cancer, fruquintinib for colorectal cancer, amivantamab for lung cancer, repotrectinib for lung cancer, tasurgratinib for biliary tract cancer, enfortumab vedotin plus pembrolizumab for urothelial cancer, and dabrafenib plus trametinib for glioma in Japan. International journal of clinical oncology. 2024
Iiji Koh, Kaoru Kawasaki, Kaori Moriuchi, Reona Shiro, Yoshie Yo, Noriomi Matsumura. Autologous Blood Donation and Transfusion in Patients with Placental Malposition: A Single-Institution Pilot Study and Systematic Literature Review. Healthcare. 2024. 12. 21. 2138
進行卵巣癌への薬物療法 臨床試験結果の解釈と診療への応用
(Ovarian Cancer Academy in Osaka 2024)
Molecular classification of ovarian high-grade serous/endometrioid carcinomas through multi-omics analysis: JGOG3025-TR2 study
(The 22nd JK Collaboration Meeting 2024)
進行卵巣癌薬物療法の新展開 ~NACの影響とsurgical outcomeを踏まえて~
(Gynecology expert seminar in Tokyo 2024)
子宮体癌に対する複合免疫療法
(Endometrial Cancer Clinical Seminar in 山形 2024)
進行卵巣癌への薬物療法 臨床試験結果の解釈と診療への応用
(Ovarian Cancer Web Seminar 2024)
2005 - 2007 Duke University Department of Obstetrics and Gynecology Division of Gynecologic Oncology
2003 - 2007 Kyoto University Graduate School of Medicine Gynecology and Obstetrics
1990 - 1996 Kyoto University Department of Medicine
Professional career (2)：
Ph.D. (Kyoto University)
M.D. (Kyoto University)
Work history (9)：
2017/04 - 現在 Kindai University Faculty of Medicine Department of Obstetrics and Gynecology Professor
2013/08 - 2017/03 Kyoto University Department of Gynecology and Obstetrics Associate Professor
2012/12 - 2013/07 Kyoto University Department of Gynecology and Obstetrics Assistant Professor (Lecturer)
2008/04 - 2012/11 Kyoto University Department of Gynecology and Obstetrics Assistant Professor
2007/04 - 2008/03 Kyoto University Hospital Department of Obstetrics and Gynecology Clinical Assistant Professor
2002/09 - 2003/03 Kyoto University Hospital Department of Obstetrics and Gynecology Medical Stuff
2000/04 - 2002/08 Toyooka Public Hospital Department of Obstetrics and Gynecology Medical Stuff
1998/05 - 2000/03 Hyogo Prefectural Amagasaki Hospital Department of Obstetrics and Gynecology Medical Stuff
1996/05 - 1998/04 Kyoto University Hospital Department of Obstetrics and Gynecology Resident
Show all
Committee career (8)：
2024/07 - 現在 日本婦人科腫瘍学会 専門医資格認定小委員会 委員長
2024/06 - 現在 Japanese Medical Specialty Board director
2020/07 - 現在 Japan Society of Gynecologic Oncology Director
2020/06 - 現在 Takara Bio Inc. Outside Director
2019/02 - 現在 Japanese Gynecologic Oncology Group Director
2017/06 - 現在 Japan Society of Obstetrics and Gynecology Vice Chairman of the Central Committee of the Specialized Medical System
2017/05 - 現在 The Obstetrical Gynecological Society of Kinki District Japan Director
2020/07 - 2024/07 日本婦人科腫瘍学会 専門医試験作成委員会 委員長
Show all
Awards (1)：
2022 - Best Doctors in Japan 2022-2023, 2024-2025
Association Membership(s) (11)：
日本ロボット外科学会
, 日本内視鏡外科学会
, International Gynecologic Cancer Society
, 日本女性医学会
, JAPAN SOCIETY FOR REPRODUCTIVE MEDICINE
, 日本産婦人科内視鏡学会
, JAPAN SOCIETY OF PERINATAL AND NEONATAL MEDICINE
, 日本婦人科腫瘍学会
, JAPAN SOCIETY OF CLINICAL ONCOLOGY
, THE JAPANESE CANCER ASSOCIATION
, JAPAN SOCIETY OF OBSTETRICS AND GYNECOLOGY
